NASDAQ:ZYXI Zynex - ZYXI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zynex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $13.64 -0.57 (-4.01%) (As of 02/3/2023 09:05 PM ET) Add Compare Share Share Today's Range$13.27▼$14.6950-Day Range$13.32▼$16.8052-Week Range$4.97▼$17.25Volume737,200 shsAverage Volume280,400 shsMarket Capitalization$510.82 millionP/E Ratio29.02Dividend YieldN/APrice Target$17.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zynex MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside25.9% Upside$17.17 Price TargetShort InterestBearish16.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 2 Articles This WeekInsider TradingSelling Shares$15,420 Sold Last QuarterProj. Earnings Growth20.93%From $0.43 to $0.52 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector228th out of 1,025 stocksElectromedical Equipment Industry4th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.17, Zynex has a forecasted upside of 25.9% from its current price of $13.64.Amount of Analyst CoverageZynex has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.89% of the float of Zynex has been sold short.Short Interest Ratio / Days to CoverZynex has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Zynex has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYXI. Previous Next 1.7 News and Social Media Coverage News SentimentZynex has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zynex this week, compared to 2 articles on an average week.Search Interest6 people have searched for ZYXI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Zynex to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,420.00 in company stock.Percentage Held by Insiders44.28% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.64% of the stock of Zynex is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 20.93% in the coming year, from $0.43 to $0.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 29.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 29.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.32.Price to Book Value per Share RatioZynex has a P/B Ratio of 7.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zynex (NASDAQ:ZYXI) StockZynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.Read More Receive ZYXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYXI Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.comZynex Monitoring Announces Community Blood Drive and Research Collaboration Trial for its Fluid Monitoring SystemJanuary 31, 2023 | finance.yahoo.comZynex Recognized in The Power 500 Healthcare Technology CompaniesFebruary 6, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 17, 2023 | finance.yahoo.comZynex Reports Preliminary Fourth Quarter 2022 ResultsDecember 22, 2022 | finance.yahoo.comZynex Ranks 11th in Forbes List of "America's Best Small Companies 2023"December 20, 2022 | finance.yahoo.comInvestors in Zynex (NASDAQ:ZYXI) have made a massive return of 400% over the past five yearsNovember 22, 2022 | finance.yahoo.comDespite recent sales, Zynex, Inc. (NASDAQ:ZYXI) insiders still hold the largest share with a 44% interestNovember 21, 2022 | finance.yahoo.comZynex Medical to Participate in Piper Sandler 34th Annual Healthcare ConferenceFebruary 6, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! November 17, 2022 | finance.yahoo.comZynex Named as a Winner in the Deloitte 2022 Technology Fast 500TM Awards for the 4th Consecutive YearNovember 4, 2022 | finance.yahoo.comZynex, Inc. (NASDAQ:ZYXI) Shares Could Be 47% Below Their Intrinsic Value EstimateOctober 31, 2022 | finance.yahoo.comDoes Zynex Inc. (ZYXI) Have the Potential to Rally 65% as Wall Street Analysts Expect?October 27, 2022 | finance.yahoo.comZynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue EstimatesOctober 27, 2022 | finance.yahoo.comZynex Announces 2022 Third Quarter EarningsOctober 26, 2022 | msn.comEarnings Outlook For ZynexOctober 19, 2022 | finance.yahoo.comHere's Why Zynex (NASDAQ:ZYXI) Has Caught The Eye Of InvestorsOctober 17, 2022 | investorplace.com7 Under-the-Radar Growth Stocks With 200% Growth Potential - InvestorPlaceOctober 13, 2022 | benzinga.comZynex, Inc. to Announce Third Quarter 2022 Financial Results - Zynex (NASDAQ:ZYXI) - BenzingaOctober 13, 2022 | finance.yahoo.comZynex, Inc. to Announce Third Quarter 2022 Financial ResultsOctober 11, 2022 | finance.yahoo.comZynex Reports Preliminary Third Quarter 2022 ResultsOctober 5, 2022 | seekingalpha.comShort Squeeze Candidate With Low PEG Ratio: Zynex (NASDAQ:ZYXI) - Seeking AlphaSeptember 21, 2022 | benzinga.comZynex Monitoring Solutions Announces First Enrollment In Blood Loss Detection Clinical Trial For CM-1600 - BenzingaSeptember 21, 2022 | finance.yahoo.comZynex Monitoring Solutions Announces First Enrollment in a Blood Loss Detection Clinical Trial for its CM-1600 Monitoring SystemSeptember 20, 2022 | globenewswire.comThe Global Physiotherapy Equipment Market to Grow at a CAGR of 7.44% by 2027 | DelveInsight - GlobeNewswireSeptember 8, 2022 | reuters.comZYXI.A - Zynex Inc. | Stock Price & Latest News | ReutersSeptember 6, 2022 | nasdaq.comDo Zynex's (NASDAQ:ZYXI) Earnings Warrant Your Attention? - NasdaqSeptember 5, 2022 | finance.yahoo.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Zynex, Inc.'s NASDAQ:ZYXI) Stock? - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZYXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYXI Company Calendar Last Earnings11/02/2021Today2/06/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZYXI CUSIPN/A CIK846475 Webwww.zynex.com Phone(303) 703-4906FaxN/AEmployees774Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.17 High Stock Price Forecast$21.00 Low Stock Price Forecast$12.50 Forecasted Upside/Downside+25.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.47 Trailing P/E Ratio29.02 Forward P/E Ratio31.72 P/E GrowthN/ANet Income$17.10 million Net Margins12.35% Pretax Margin16.06% Return on Equity26.05% Return on Assets14.78% Debt Debt-to-Equity Ratio0.10 Current Ratio3.41 Quick Ratio2.68 Sales & Book Value Annual Sales$130.30 million Price / Sales3.92 Cash Flow$0.51 per share Price / Cash Flow26.91 Book Value$1.93 per share Price / Book7.07Miscellaneous Outstanding Shares37,450,000Free Float21,565,000Market Cap$510.82 million OptionableOptionable Beta0.66 Key ExecutivesThomas SandgaardChairman, President & Chief Executive OfficerAnna LucsokChief Operating OfficerDaniel J. MoorheadChief Financial OfficerChelle van BurkleoVice President-SalesDave AnttilaDirector-Human ResourcesKey CompetitorsAxoGenNASDAQ:AXGNEdap TmsNASDAQ:EDAPViewRayNASDAQ:VRAYBioLife SolutionsNASDAQ:BLFSOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsHancock Whitney CorpBought 16,049 shares on 2/3/2023Ownership: 0.043%Spire Wealth ManagementSold 3,300 shares on 2/3/2023Ownership: 0.008%Bailard Inc.Bought 10,200 shares on 2/2/2023Ownership: 0.027%Gladius Capital Management LPSold 1,564 shares on 2/2/2023Ownership: 0.007%Simplex Trading LLCSold 24,100 shares on 2/2/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ZYXI Stock - Frequently Asked Questions Should I buy or sell Zynex stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZYXI shares. View ZYXI analyst ratings or view top-rated stocks. What is Zynex's stock price forecast for 2023? 3 brokers have issued 12 month price objectives for Zynex's shares. Their ZYXI share price forecasts range from $12.50 to $21.00. On average, they expect the company's share price to reach $17.17 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View analysts price targets for ZYXI or view top-rated stocks among Wall Street analysts. How have ZYXI shares performed in 2023? Zynex's stock was trading at $13.91 at the beginning of 2023. Since then, ZYXI stock has decreased by 1.9% and is now trading at $13.64. View the best growth stocks for 2023 here. When is Zynex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our ZYXI earnings forecast. How were Zynex's earnings last quarter? Zynex, Inc. (NASDAQ:ZYXI) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.05. The business earned $34.79 million during the quarter, compared to analyst estimates of $35.42 million. Zynex had a trailing twelve-month return on equity of 26.05% and a net margin of 12.35%. What guidance has Zynex issued on next quarter's earnings? Zynex issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 17th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $48.00 million-$51.00 million, compared to the consensus revenue estimate of $49.71 million. What is Thomas Sandgaard's approval rating as Zynex's CEO? 81 employees have rated Zynex Chief Executive Officer Thomas Sandgaard on Glassdoor.com. Thomas Sandgaard has an approval rating of 87% among the company's employees. What is Zynex's stock symbol? Zynex trades on the NASDAQ under the ticker symbol "ZYXI." Who are Zynex's major shareholders? Zynex's stock is owned by a number of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.49%), Bridge City Capital LLC (0.35%), Janney Montgomery Scott LLC (0.17%), Legato Capital Management LLC (0.12%), Yousif Capital Management LLC (0.06%) and Platte River Wealth Advisors LLC (0.05%). Insiders that own company stock include Anna Lucsok, Daniel J Moorhead and Thomas Sandgaard. View institutional ownership trends. How do I buy shares of Zynex? Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zynex's stock price today? One share of ZYXI stock can currently be purchased for approximately $13.64. How much money does Zynex make? Zynex (NASDAQ:ZYXI) has a market capitalization of $510.82 million and generates $130.30 million in revenue each year. The company earns $17.10 million in net income (profit) each year or $0.47 on an earnings per share basis. How many employees does Zynex have? The company employs 774 workers across the globe. How can I contact Zynex? Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The official website for the company is www.zynex.com. The company can be reached via phone at (303) 703-4906 or via email at info@zynex.com. This page (NASDAQ:ZYXI) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.